New Jersey is currently home to 1665 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Longitudinal Sexual and Reproductive Health Study of Women with Breast Cancer and Lymphoma
NCT01788839
Recruiting
The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the ability to have children (fertility). These blood draws are optional and the patient can still participate in the questionnaire portion of the study even if they choose not to have their blood drawn.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Conditions: Breast Cancer, Lymphoma, Hodgkin's Lymphoma
Register for Updates
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
NCT06347133
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: Overlook Medical Center, Summit, New Jersey
Conditions: Hypertriglyceridemia
Register for Updates
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer
NCT06614192
Recruiting
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused ABBV-400 to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC). ABBV-400 is an investigational drug being developed for the treatment of CRC. Participants are put int... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Rutgers Cancer Institute of New Jersey /ID# 268056, New Brunswick, New Jersey
Conditions: Metastatic Colorectal Cancer
Register for Updates
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763
Recruiting
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Hackensack Medical Center, Hackensack, New Jersey
Conditions: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Register for Updates
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
NCT04486833
Recruiting
The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer. The study is comprised of a Phase 1 dose escalation portion and two Pha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: The Valley Hospital - Luckow Pavilion, Paramus, New Jersey
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
A Safety and Efficacy Study of a Nutraceutical in Aging Males with Thinning Hair
NCT06854575
Recruiting
A study to assess the safety and efficacy of a dietary supplement when used over the course of 9 months by men with self-perceived hair thinning.
Gender:
MALE
Ages:
Between 40 years and 65 years
Trial Updated:
03/20/2025
Locations: SGS Elizabeth Research Center, Elizabeth, New Jersey
Conditions: Hair Thinning
Register for Updates
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT05558982
Recruiting
Single-arm, open label study to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in the second-line metastatic setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891
Recruiting
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Investigate Efficacy and Safety of Carisbamate As Adjunctive Treatment for Seizures Associated with LGS in Children and Adults
NCT05219617
Recruiting
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).
Gender:
ALL
Ages:
Between 4 years and 55 years
Trial Updated:
03/20/2025
Locations: Northeast Regional Epilepsy Group, Hackensack, New Jersey
Conditions: Seizures, Lennox Gastaut Syndrome
Register for Updates
Phase IB/II of CPX-351 for Relapse Prevention in AML
NCT04990102
Recruiting
This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on D1 only, every 28 days pending toxicity. The maximum tolerated dose will be used for the phase II expansion portion of the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Acute Myeloid Leukemia (AML) in Remission
Register for Updates
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
NCT04958811
Recruiting
To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Non-squamous Non-small-cell Lung Cancer
Register for Updates
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT03572374
Recruiting
The purpose of this study is learn more about how being treated for breast cancer affects patients' employment. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs during and after treatment. The app provides advice for patients to use when having conversations about breast cancer with their employers and their doctors. The app is called TEAMWork (Talking to Employers And Medical staff about Work). In this study, the investigators are... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Memorial Sloan Kettering Basking Ridge (Consent and Follow-up), Basking Ridge, New Jersey
Conditions: Breast Cancer
Register for Updates